Semaglutide is a GLP-1 receptor agonist with approved medicines, but the molecule's name does not describe one interchangeable product. The formulation, approved indication and population determine which evidence applies. FDA's 2026 Wegovy labeling includes injection and tablet presentations with indication-specific distinctions. A reader should therefore identify the exact product before interpreting an article about weight management or cardiovascular outcomes. FDA Wegovy prescribing information 2026

Reading the evidence precisely

An approval for one use does not establish every proposed use of semaglutide. A trial may enroll adults without diabetes, people with established cardiovascular disease, or patients with a defined liver condition. Differences in baseline risk affect both the expected benefit and the relevance of adverse events. An average trial result also describes a group rather than predicting one person's response.

For educational comparisons, record the trial population, comparator, follow-up period and outcome before discussing the size of an effect. Weight change, glucose control and clinical cardiovascular events answer different questions. Combining those outcomes into a single claim of overall superiority obscures the decision the study actually tested.

Product quality remains a separate question

The prescribing information describes a regulated finished medicine. It cannot authenticate a separately sold vial, powder, tablet or spray bearing the word semaglutide. Approval evidence is therefore not a substitute for product identity and supply-chain verification.

Semaglutide also has clinically important contraindications, warnings and interactions. The label includes a boxed thyroid C-cell tumor warning and other precautions that require individualized clinical interpretation. This article provides an evidence-reading framework, not treatment selection or administration instructions. The publication check should confirm the latest product label rather than recycling an older list of indications or warnings.